Home > Oncology > Adding ribociclib to letrozole boosts survival in some with advanced breast cancer

Adding ribociclib to letrozole boosts survival in some with advanced breast cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The New England Journal of Medicine
Reuters Health - 09/03/2022 - First-line therapy with the combination of ribociclib and letrozole increased overall survival by 24% over letrozole alone among patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to final results from the MONALEESA-2 phase-3 study. Median overall survival was 63.9 months with the combination compared with 51.4 months when letrozole was given with placebo (P=0.008), researchers report in the New England Journal of Medicine. After a median follow-up of 6.6 years, 54.2% of ribociclib recipients had died versus 65.6% of placebo patients. Novartis, which paid for the study of 668 women and markets the CDK4/6 inhibitor under the brand name Kisqali, originally released the survival data in September. "The Kaplan-Meier analysis shows that the overall survival benefit of ribociclib began to emerge at approximately 20 months and continued to increase with longer follow-up, as indicated by ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on